Comparative evaluation of efficacy of single pre-emptive dose of Extended release Lornoxicam versus Prolonged release Diclofenac for surgical removal of impacted 3rd molar in Indian population: A prospective, randomized, triple blind, split mouth clinical trial. - NIL

开始日期2024-03-02

申办/合作机构-

NCT05679453

/ Completed临床4期IIT

Comparison of Lornoxicam and Etodolac on Edema, Trismus and Pain After Third Molar Surgery

Our study aimed to compare the effect of lornoxicam and etodolac on postoperative pain, edema and trismus following lower third molar extraction

开始日期2022-07-20

申办/合作机构-

CTRI/2022/03/041484

/ Not yet recruitingN/AIIT

EFFICACY OF PREOPERATIVE INTRAVENOUSLORNOXICAM ON ATTENUATING THEHEMODYNAMIC RESPONSES FOLLOWINGLARYNGOSCOPY AND ENDOTRACHEALINTUBATION

开始日期2022-03-31

申办/合作机构-

100 项与氯诺昔康相关的临床结果

登录后查看更多信息

100 项与氯诺昔康相关的转化医学

登录后查看更多信息

100 项与氯诺昔康相关的专利（医药）

登录后查看更多信息

1,235

项与氯诺昔康相关的文献（医药）

2025-07-03·JOURNAL OF DRUG TARGETING

Formulation, optimisation, and evaluation of Lornoxicam-loaded Novasomes for targeted ulcerative colitis therapy: in vitro and in vivo investigations

Article

作者: Darwish, Asmaa Badawy ; Essam Ibrahim Al-Samadi, Inas ; Salama, Abeer

The purpose of this work was to create and assess Lornoxicam (LOR) loaded Novasomes (Novas) for the efficient treatment of ulcerative colitis. The study was performed using a 2³ factorial design to investigate the impact of several formulation variables. Three separate parameters were investigated: Surface Active agent (SAA) type (X₁), LOR concentration (X₂), and SAA: Oleic acid ratio (X₃). The dependent responses included encapsulation efficiency (Y₁: EE %), particle size (Y₂: PS), zeta potential (Y₃: ZP), and polydispersity index (Y₄: PDI). The vesicles demonstrated remarkable LOR encapsulation efficiency, ranging from 81.32 ± 3.24 to 98.64 ± 0.99%. The vesicle sizes ranged from 329 ± 9.88 to 583.4 ± 9.04 nm with high negative zeta potential values. The release pattern for Novas' LOR was biphasic and adhered to Higuchi's model. An in-vivo study assessed how LOR-Novas affected rats' acetic acid-induced ulcerative colitis (UC). The optimised LOR-Novas effectively reduced colonic ulceration (p < 0.05) and reduced the inflammatory pathway via inhibiting Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ) and inducible nitric oxide (iNO). At the same time, it elevated Silent information regulator-1(SIRT-1) and reduced glutathione (GSH) colon contents. Thus, the current study suggested that the formulation of LOR-Novas may be a viable treatment for ulcerative colitis.

2025-07-01·JOURNAL OF MOLECULAR LIQUIDS

A sustainable and comprehensive protocol for spectrofluorimetric assay of lornoxicam in pharmaceutical dosage forms using biomass-based carbon dots: Evaluation of whiteness, greenness, and blueness of the methodology

作者: katamesh, Noha S. ; Abdel-Lateef, Mohamed A. ; Gomaa, Hassanien ; Darwish, Ibrahim A.

In this study, water-soluble carbon dots (B-CDs) were synthesized from the peel of red pitaya fruits.The synthesized B-CDs were characterized and recognized by optical, microscopical, and spectroscopical techniques.In addition, the quantum yield of the prepared B-CDs was determinedThe prepared B-CDs exhibit distinctive fluorescence spectra at 369.5 nm and 441.5 nm for excitation and emission, resp.On the other hand, lornoxicam exhibits a UV-absorbance spectrum with the highest peak of 370 nm, which thoroughly overlapped with fluorescence excitation of the prepared B-CDs and competed with its absorption.Consequently, the fluorescence of the prepared B-CDs was quenched, and a novel fluorescence anal. method was developed to determine lornoxicam based on the primary inner filter effect mechanism.The validation of the method exhibited a linearity of 1.5-12.0 μg/mL with a detection limit of 0.405 μg/mL in addition to satisfactory recovery and accuracy.The study has effectively measured the amount of lornoxicam in different types of pharmaceutical dosage forms.Moreover, to ensure environmental sustainability, greener solvents were chosen in place of hazardous solvents, utilizing the Green Solvents Selecting Tool.Anal. Eco scale, NEMI, AGREE and Agree prep algorithms, SPMS, and Complex-GAPI, as well as an extensive greenness anal., proved the technique′s advantageous ecol. characteristics.In addition, the recent RGB12 and BAGI algorithms were applied to evaluate the greenness framework and were introduced as tools for examining the "whiteness" and "blueness" of the work.

2025-06-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Multimodal evaluation of lipoxygenase-targeting NSAIDs using integrated in vitro, SAR, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation approaches

Article

作者: Hayat, Muhammad Munawar ; Ashraf, Muhammad ; Ejaz, Samina ; Iqbal, Ambar ; Riaz, Naheed ; Abbas, Wasim ; Ashok, Avinash Karkada

Lipoxygenase (LOX) and cyclooxygenase (COX) pathways generate biologically active mediators implicated in inflammatory disorders and several classes of cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX pathway by inhibiting the COX-1 and COX-2 enzymes. We reported earlier that several NSAIDs, including naproxen, aspirin and acetaminophen, inhibited lipoxygenase (LOX) enzyme at sub-micromolar concentrations. In continuation, the present work demonstrates the anti-LOX activity of nine more NSAIDs supported by in vitro, in silico, MD simulation and breast cancer cell line studies. All tested drugs displayed potent to excellent inhibitory profiles with IC₅₀ values <24.93 ± 0.64 μM. Aceclofenac (IC₅₀ 0.85 ± 0.06 μM) was the most active drug, followed by indomethacin (IC₅₀ 1.13 ± 0.07 μM), meloxicam (IC₅₀ 1.94 ± 0.07 μM) and ketorolac (IC₅₀ 9.26 ± 0.82 μM). Celecoxib (IC₅₀ 15.81 ± 0.71 μM), lornoxicam (IC₅₀ 16.54 ± 0.28 μM) and nimesulide (IC₅₀ 19.87 ± 0.85 μM) showed excellent inhibitory profiles. Flurbiprofen (IC₅₀ 21.73 ± 0.93 μM) and etoricoxib (IC₅₀ 24.93 ± 0.64 μM) moderately inhibited the target enzyme. SAR studies revealed that active molecules decorated with the carboxylate group afforded strong binding interactions as observed by in vitro assays and structural features. Other drugs, including enol derivatives and celecoxib, also showcased enhanced binding interactions. However, the cytotoxic effects of NSAIDs against the MCF-7 breast cancer cell line did not disclose significant anticancer activity. Molecular docking studies against human 5-LOX offered the best binding affinities for aceclofenac (-13.54 kcal/mol), accompanied by conventional hydrogen bonding and hydrophobic interactions as supported by the in vitro results. Docking studies with DNA dodecamer established minor groove binding with their possible role in DNA replication and gene expression. Density functional theory (DFT) and ESP studies, MD simulations and MMPBSA free energy calculations further reiterated the stability of ligand-receptor complexes. Overall, these findings highlight the potential of targeted NSAIDs as dual COX/LOX inhibitors with broader therapeutic relevance in inflammatory disorders.

项与氯诺昔康相关的新闻（医药）

2025-07-18

·赛柏蓝

第十一批国采新消息，规则大幅优化！

作者 | 凯西编辑 | 郑瑶7月15日，国采办发布《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》，16日-31日16:00间，符合条件的上市许可持有人或生产企业均可参与信息填报。预计之后将进入医疗机构报量、发布集采文件、开标、确认拟中选结果等阶段。规则优化之下，不再单一卷价格成为可能。01第十一批集采新动向反对低于成本的价格内卷前十批国采的品种价格降幅基本维持在48%-59%之间，第十批国采创下新高，超过60%。来到第十一批集采，国家医保局明确表态，规则将坚持“稳临床、保质量、防围标、反内卷”的原则。对于有投标资格的国内仿制药企业来说，规则最大的变化无疑是此次集采将继续对企业价差作出一定限制，但对价差的计算“锚点”作出优化，不再简单选用最低报价作为参照。以往的1.8倍熔断机制下，报价超过同组最低报价1.8倍的企业自动淘汰出局，即便复活对于后续的分量也有较大的影响。如果熔断机制不再取最低价，而是选择一个相对合理的“折中”价格，对于企业的报价策略将产生极大的影响，甚至可能直接降低平均降幅。同时，超低报价的企业将成为第十一批集采关注的重点，国家医保局将要求其对报价的合理性作出解释，承诺不低于成本报价。显然，国家医保局已经释放尊重企业合理利润空间的信号。对于以往容易出现超低报价的具有成本规模效应的大型药企和轻资产的B证企业来说，在报出低价时也要将后续面临的监管纳入考虑，中选仅仅是开始，在整个采购周期内供应质量疗效安全性有保证的药品是参与集采的重中之重。国家药监局药品监管司相关人士强调，对价格降幅大、生产管理风险高的药品加大检查和抽检力度，重点关注中选药品原辅料、生产工艺等变更情况。赛柏蓝获悉，B证企业参与集采的机会和其他企业是一样的，但是其运营方式的特点是主体多、链条长，管理不统一，从而导致的潜在质量风险使得其成为重点关注的监管对象之一。第十一批集采质量要求趋严，一个重要变化是——投标药品的上市许可持有人或受托生产企业应当具有2年以上同类型制剂生产经验，投标药品应当通过上市前的药品GMP符合性检查，并将原来的“投标药品”2年内不违反药品GMP要求，扩展到“投标药品的生产线”2年内不违反药品 GMP要求。相关人士对赛柏蓝表示，有一些企业可能拿到了药品批文，但是相关生产机构没有通过上市前的药品GMP符合性检查，那么是没有资格参与国家组织药品集采的。另一个最重要的规则变化可能是第十一批集采在“按药品通用名报量”外，增加“按具体品牌报量”的选项，如果原研厂家的中选积极性提升，将更好的满足临床多元的用药需求。赛柏蓝从国家医保局相关人士处了解到，对国家组织药品集采的规则不断调整优化的考量之一是尽可能模拟市场机制作用下的竞争状态，极低价、低于成本报价从来不是想看到的结果，国家组织药品集采更不是对任何一个药品都想砍掉一刀，所以此次再次重申集采非新药，新药不集采。0255个品种440亿规模竞争一触即发米内网数据显示，55个品种2024年在中国公立医疗机构终端的销售额合计接近440亿元，整体市场规模相对较小，在前11批国采中市场规模排名第八，55个品种销售额均在1亿元以上，其中超10亿大品种11个，包括达格列净口服常释剂型、奥司他韦颗粒剂、法莫替丁注射剂、苯唑西林注射剂、罗沙司他口服常释剂型、洛索洛芬贴剂、溴己新注射剂、复方醋酸钠林格注射液/钠钾镁钙葡萄糖注射液、奥拉帕利口服常释剂型、二羟丙茶碱注射剂等。截至7月16日，55个品种涉及原研厂家26家。其中，阿斯利康涉及奥拉帕利口服常释剂型（市场份额100%）、达格列净口服常释剂型（市场份额94.29%）、福莫特罗吸入剂3个品种；大冢制药涉及瑞巴派特口服常释剂型（市场份额32.5%）、西洛他唑口服常释剂型（市场份额75.48%）、丙卡特罗吸入剂（市场份额0.99%）3个品种；雅培涉及腺苷蛋氨酸注射剂（市场份额44.41%）、氟伏沙明口服常释剂型（市场份额29.26%）两个品种；诺华涉及艾曲泊帕乙醇胺口服常释剂型（市场份额91.23%）、奥卡西平口服常释剂型（市场份额67.12%），其余原研厂家如默沙东、第一三共、法国益普生、拜耳、武田、施维雅、晖致、罗氏、勃林格殷格翰多数涉及1个品种。有品种通过一致性评价的厂家402家，预计随着时间的推移，符合参与资格的药企还会增加。涉及产品较多的厂家分别是倍特药业（16个）、科伦药业（15个）、复星医药（15个）、石家庄四药（14个）、正大制药（13个）、福安药业（12个）、石药集团（12个）、齐鲁制药（10个）、新和成（10个）。竞争激烈的品种依然不在少数，头孢唑肟注射剂符合参与条件企业达42家，法莫替丁注射剂、二羟丙茶碱注射剂竞争厂家达40家；地氯雷他定口服液体剂竞争厂家达30家；竞争厂家超过20家的品种还有达格列净口服常释剂型（26+1家）、腺苷钴胺口服常释剂型（23+0家）、美索巴莫注射剂（22+0家）、氯诺昔康注射剂（21+1家）、福莫特罗吸入剂（21+1家）、氟伏沙明口服常释剂型（20+1家）。综合销售额、竞争厂家来看，达格列净口服常释剂型、法莫替丁注射剂目前来看可能是竞争最激烈的品种。第十一批国采的规则优化之下，无理性的价格内卷可能不再是最优选择。拟纳入第十一批集采的品种资料来源：米内网数据库、上海阳光医药采购网等END内容沟通：郑瑶（13810174402）

带量采购

2025-07-15

·医药代表

第十一批国采报量启动！这55个品种有你的吗？

一些小伙伴可以紧张起来了，第十一批国采来了，已经启动报量！今日（7 月 15 日），国家联采办发布了《关于开展第十一批国家组织药品集中采购相关药品信息填报工作的通知》。《通知》显示，按照第十一批国家组织药品集中采购进度安排，国家组织药品联合采购办公室启动第十一批国家组织药品集中采购相关药品信息填报工作，共有 55 个药品拟纳入第十一批国采，名单如下：#品种名称1倍他米松注射剂2地氯雷他定口服液体剂3卢帕他定口服常释剂型4阿瑞匹坦口服常释剂型5福沙匹坦双葡甲胺注射剂6奥拉帕利口服常释剂型7右丙亚胺（右雷佐生）注射剂8达格列净口服常释剂型9二甲双胍恩格列净片(I)10普伐他汀口服常释剂型11硫酸镁钠钾口服用浓溶液12法莫替丁注射剂13瑞巴派特口服常释剂型14腺苷蛋氨酸注射剂15尼可地尔口服常释剂型16贝尼地平口服常释剂型17贝前列素口服常释剂型18西洛他唑口服常释剂型19阿伐曲泊帕口服常释剂型20艾曲泊帕乙醇胺口服常释剂型21腺苷钴胺口服常释剂型22罗沙司他口服常释剂型23地诺孕素口服常释剂型24钆布醇注射剂25美索巴莫注射剂26阿仑膦酸口服常释剂型27洛索洛芬贴剂/洛索洛芬贴膏剂28甲氧氯普胺注射剂29氯诺昔康注射剂30二羟丙茶碱注射剂31沙丁胺醇注射剂32丙卡特罗吸入剂33溴己新注射剂34福莫特罗吸入剂35异烟肼注射剂36奥司他韦颗粒剂37阿莫西林克拉维酸口服液体剂38头孢丙烯口服液体剂39头孢唑肟注射剂40苯唑西林注射剂41去氧肾上腺素注射剂42肾上腺素注射剂43碳酸氢钠注射剂44复方醋酸钠林格注射液/钠钾镁钙葡萄糖注射液45复方电解质注射剂46复方电解质注射剂（Ⅱ）47维库溴铵注射剂48布比卡因注射剂49阿戈美拉汀口服常释剂型50氟伏沙明口服常释剂型51尼麦角林口服常释剂型52奥卡西平口服常释剂型53多巴丝肼口服常释剂型54吡拉西坦（乙酰胺吡咯烷酮）口服常释剂型55尼达尼布口服常释剂型一般来说，报量名单基本就是正式名单了，《采购文件》发布时很少有调整，粗略看了下，都在之前业界流传的征求意见的第 11 批国采拟采购药品清单之中。据环球网报道，国家医保局相关司负责人介绍，第十一批国采经过三阶段筛选，将此 55 个品种纳入第十一批集采报量范围，采购规则总体将坚持“稳临床、保质量、防围标、反内卷”的原则。▌月底完成第 11 批国采报量按照报量要求，自 2025 年 7 月 16 日起，国家医保服务平台（网址：fuwu.nhsa.gov.cn）面向企业开放信息填报通道。持有填报范围内药品参比制剂或通过质量和疗效一致性评价仿制药注册证的上市许可持有人或生产企业均可参加（境外上市许可持有人由境内代理人填报）。需要注意的是，据《通知》，报量系统将于 2025 年 7 月 31 日 16:00 停止填报，截至 7 月 31 日 17:00 审核通过的各厂牌药品信息将作为本次医疗机构填报需求量的选择范围；未在规定时间内填报信息并提交的药品，将不纳入医疗机构填报需求量的选择范围。除此之外，随《通知》还发布了《评数量达到条件未纳入第十一批集采的药品》，以及具体原因，详情可以查看 MRCLUB 今日另一则推送。你的品种被纳入第 11 批国采报量名单了吗？欢迎留言分享~相关阅读：官宣了！单国洪加入百济神州创新药要起飞啦！国家发布目录准入、挂网、进院支持政策2025国家医保药品目录调整工作方案来了9900万“攻坚”基金加持！齐鲁制药牵手国自然开新局一药企办公点遭百人“围攻”大三甲医院院长，多次违规吃喝被通报确认了！上市药企副总裁被留置官宣！这家跨国药企要更名了药企董事被查！器械老板行贿被罚药企销售挪用货款三年，支付流水露马脚反制！部分进口医疗器械限制采购2024年度中国医药工业百强(名单)央视暗访，“网红医生”背后的生意经柯玉雄加入GSK，北大医药新总裁确定钱江就任百时美施贵宝中国总经理用AI开发新药，又一家外企行动了两家药企公开致歉！四十年，一家跨国药企的中国故事超10亿元大品种，多家药企被停采两省卫健委，财务人员被查医药人变身公益侠，全球公益接力正式版来了！2025国谈时间确定2024年全球药品销售20强金赛药业全国招募火热启动百万人从社会“消失”，药企VR破局官宣了，国药股份董事长确定康方生物代表被查，官方结果公布一药企总裁被罚1500万，10年禁入MRCLUB原创作者招募中数十万精准会员每日阅读，助您快速提升个人品牌，扩大在医药行业及社会化媒体的影响力！（详情请访问网站http://wemr.club）医药代表伴您成长！

带量采购一致性评价

2025-07-15

·药筛

11批国采目录官宣，55个品种，规模400亿+，附最新竞争格局

11批国采目录官宣。有专利争议的沙库巴曲缬沙坦不在；生产经验不足两年的洛索洛芬贴剂在；销售金额很低的丙卡特罗吸入剂也在；目录永远是个玄学！附上产品最新竞争格局品种名称企业数销售规模份额最大企业占比份额最大企业倍他米松注射剂124.5129.05%国药容生地氯雷他定口服液体剂293.5567.89%海南普利卢帕他定口服常释剂型114.0485.64%扬子江药业阿瑞匹坦口服常释剂型77.0660.91%齐鲁福沙匹坦双葡甲胺注射剂79.0668.76%正大天晴奥拉帕利口服常释剂型912.03100.00%阿斯利康右雷佐生注射剂76.5499.54%奥赛康达格列净口服常释剂型2940.8997.60%阿斯利康二甲双胍恩格列净片(I)132.09100.00%中美华东普伐他汀口服常释剂型910.2565.07%第一三共硫酸镁钠钾口服用浓溶液171.1468.42%济川药业法莫替丁注射剂4128.4315.97%山西威奇达光明瑞巴派特口服常释剂型158.7354.87%浙江远力健腺苷蛋氨酸注射剂99.1648.03%雅培尼可地尔口服常释剂型137.8946.89%中外制药贝尼地平口服常释剂型106.4856.17%协和麒麟贝前列素口服常释剂型1010.4988.47%北京泰德西洛他唑口服常释剂型82.8874.65%大冢阿伐曲泊帕口服常释剂型178.61100.00%AkaRx艾曲泊帕乙醇胺口服常释剂型125.01100.00%诺华腺苷钴胺口服常释剂型206.7730.72%华北制药罗沙司他口服常释剂型1919.81100.00%珐博进地诺孕素口服常释剂型114.0190.27%Jenapharm钆布醇注射剂72.0593.66%拜耳美索巴莫注射剂223.41100.00%吴中医药阿仑膦酸口服常释剂型107.2880.91%欧加农洛索洛芬贴剂719.0670.41%湖南九典甲氧氯普胺注射剂81.4830.41%遂成药业氯诺昔康注射剂213.8444.79%浙江震元二羟丙茶碱注射剂3711.3877.94%吉林津升沙丁胺醇注射剂112.0651.94%苏州泓森丙卡特罗吸入剂100溴己新注射剂1617.2625.78%石家庄四药福莫特罗吸入剂200.8292.68%重庆德润笙异烟肼注射剂101.6445.12%西南药业奥司他韦颗粒剂830.54100.00%东阳光阿莫西林克拉维酸口服液体剂63.0823.38%华南泰复头孢丙烯口服液体剂81.8969.84%南京亿华头孢唑肟注射剂4046.8239.81%西南药业苯唑西林注射剂1326.8337.01%四川制药去氧肾上腺素注射剂172.0185.07%上海禾丰肾上腺素注射剂112.8632.17%远大医药碳酸氢钠注射剂186.9317.89%四川科伦复方醋酸钠林格注射液/钠钾镁钙葡萄糖注射液1212.1438.14%南京正大天晴复方电解质注射剂81.9944.72%成都国为复方电解质注射剂 ( Ⅱ )191.6891.07%德国贝朗维库溴铵注射剂91.5952.20%山西振东泰盛布比卡因注射剂82.7529.09%上海禾丰阿戈美拉汀口服常释剂型179.5482.70%江苏豪森氟伏沙明口服常释剂型196.0667.49%丽珠尼麦角林口服常释剂型115.345.85%昆山龙灯瑞迪奥卡西平口服常释剂型95.7772.62%诺华多巴丝肼口服常释剂型148.9896.55%罗氏吡拉西坦口服常释剂型82.9154.30%江西亿友尼达尼布口服常释剂型75.4688.28%勃林格殷格翰用摩熵药筛小程序，查询产品最新竞争格局！

CSCO会议

100 项与氯诺昔康相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01866	氯诺昔康	M01AC05	DB06725

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
滑囊炎	日本	Taisho Pharmaceutical Co., Ltd.	2001-02-02
颈臂综合征	丹麦	-	1997-01-01
腰痛	丹麦	-	1997-01-01
神经痛	丹麦	-	1997-01-01
骨关节炎	丹麦	-	1997-01-01
疼痛	丹麦	-	1997-01-01
术后疼痛	丹麦	-	1997-01-01
肩周炎	丹麦	-	1997-01-01
风湿性疾病	丹麦	-	1997-01-01
类风湿关节炎	丹麦	-	1997-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头痛	临床2期	美国	POZEN, Inc.	2005-12-01
偏头痛	临床2期	美国	POZEN, Inc.	2005-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01117948 (CTgov)	临床2期	阿尔茨海默症	219	Lornoxicam (Lornoxicam)	鹽遞窪網襯鹹構鏇觸膚(糧鹹簾鬱選艱網願窪築) = 淵艱艱範廠獵鹹鹽壓艱遞艱淵簾鹹願積壓繭範 (鏇選網窪憲築鹽艱齋糧, 6.75) 更多	-	2012-11-29
				Placebo (Placebo)	鹽遞窪網襯鹹構鏇觸膚(糧鹹簾鬱選艱網願窪築) = 蓋構製膚網顧積衊觸築遞艱淵簾鹹願積壓繭範 (鏇選網窪憲築鹽艱齋糧, 7.84) 更多